Preserved in Portico This version is not peer-reviewed
Future Considerations for the mRNA–Lipid Nanoparticle Vaccine Platform
: Received: 17 December 2020 / Approved: 21 December 2020 / Online: 21 December 2020 (10:26:54 CET)
: Received: 23 December 2020 / Approved: 24 December 2020 / Online: 24 December 2020 (13:51:51 CET)
A peer-reviewed article of this Preprint also exists.
Journal reference: Current Opinion in Virology 2021
Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccine candidates against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology.
mRNA-LNP vaccines; side effects; dendritic cells
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.